FDA Approves Ryoncil for Steroid-Refractory Acute Graft-Versus-Host After Allo-HSCT
Ryoncil is first FDA-approved mesenchymal stromal cell therapy for pediatric patients aged 2 months or older
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.